DUBLIN, Sept. 19, 2017 /PRNewswire/ -- For over 17
years, the highly-coveted Allure Best of Beauty Breakthrough
Awards have recognized hair, makeup and skin products, fragrances
and devices for their innovative formulations, performance
and technologies. Today Allergan plc (NYSE: AGN) is happy to
announce that Allure has awarded the 2017 Best of Beauty
Breakthrough Award to three of the company's products: JUVÉDERM
VOLBELLA® XC, RHOFADE® (oxymetazoline HCl)
cream 1%, and SkinMedica® Lytera 2.0 Pigment Correcting
Serum.
"As a company, Allergan is committed to innovation and
developing products that meet evolving patient needs, which is why
we continue to be a leader in the aesthetic and medical dermatology
categories," said Bill Meury, Chief
Commercial Officer at Allergan, "We are proud and grateful
that Allure has recognized this commitment with their
prestigious Beauty Breakthrough Award."
JUVÉDERM VOLBELLA® XC was honored marking the second
Allure Beauty Breakthrough award for the
JUVÉDERM® collection of fillers (JUVÉDERM
VOLUMA® XC won in 2014). Both products feature Allergans
proprietary VYCROSS® technology.This second win for the
collection emphasizes the brand's position as the dermal filler
category leader and recognizes the technology's tailored gel
properties and specialized filler product offerings for specific
treatment areas. JUVÉDERM VOLBELLA® XC adds subtle
volume to lips and softens the appearance of vertical lip lines in
adults over the age of 21.1-4
A 2017 addition to Allergan's Medical Dermatology portfolio,
RHOFADE® cream was also named an Allure Beauty
Breakthrough Award winner. RHOFADE® cream is a
prescription medicine used on the skin to treat ongoing facial
redness due to rosacea in adults.5 Since FDA approval in
January, the brand has made great strides in educating media and
consumers about ongoing facial redness due to rosacea.
Finally, Allure named SkinMedica®
Lytera® 2.0 Pigment Correcting Serum a breakthrough
product, which marks the fifth time SkinMedica® has won
an Allure Beauty Award, and the second time the brand has
earned the publication's breakthrough accolade. This is also the
fourth editorial award for Lytera® 2.0 since launch,
adding to the nine wins collected by the product's predecessor,
Lytera® Skin Brightening Complex. SkinMedica®
Lytera® 2.0 Pigment Correcting Serum is an advanced
pigment-correcting serum with an innovative formula that is retinol
and hydroquinone free that reduces the appearance of existing skin
discoloration and supports the skin's ability to resist
intrinsic and extrinsic factors that can cause reoccurring and
future discoloration.
The 2017 Beauty Breakthrough Award winners will be announced in
the October issue of Allure.
JUVÉDERM VOLUMA® XC and JUVÉDERM
VOLBELLA® XC Important Information
APPROVED USES
JUVÉDERM VOLUMA® XC injectable gel is for deep
injection in the cheek area to correct age-related volume loss in
adults over the age of 21.
JUVÉDERM VOLBELLA® XC injectable gel is
for injection into the lips for lip augmentation and for correction
of perioral rhytids in adults over the age of 21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive JUVÉDERM
VOLUMA® XC or JUVÉDERM VOLBELLA® XC
injectable gels?
Do not use these products if you have a history of multiple
severe allergies or severe allergic reactions (anaphylaxis), or if
you are allergic to lidocaine or Gram-positive bacterial proteins
used in these products.
What precautions should my doctor advise me about?
- Tell your doctor if you are pregnant or breastfeeding. The
safety of these products for use during pregnancy or while
breastfeeding has not been studied
- The safety of JUVÉDERM VOLUMA® XC in patients
under 35 years or over 65 years, and the safety of JUVÉDERM
VOLBELLA® XC in patients under 22 years has not
been studied
- The safety and effectiveness of JUVÉDERM
VOLUMA® XC in areas other than the cheek area,
and JUVÉDERM VOLBELLA® XC in areas other than the
lips and perioral area have not been established in controlled
clinical studies
- Tell your doctor if you have a history of excessive scarring
(eg, hypertrophic scarring and keloid formations) or pigmentation
disorders, as use of these products may result in additional scars
or changes in pigmentation
- Tell your doctor if you are planning other laser treatments or
a chemical peel, as there is a possible risk of inflammation at the
treatment site if these procedures are performed after
treatment
- Patients who experience skin injury near the site of injection
with these products may be at higher risk for side effects
- Tell your doctor if you are on immunosuppressive therapy used
to decrease the body's immune response, as use of these products
may result in an increased risk of infection
- Tell your doctor if you are using medications that can prolong
bleeding, such as aspirin, ibuprofen, or other blood thinners, as
this may result in increased bruising or bleeding at the injection
site
- Minimize strenuous exercise, exposure to extensive sun or heat,
and alcoholic beverages within the first 24 hours following
treatment
What are possible side effects?
The most common side effects included swelling, tenderness,
bruising, firmness, lumps/bumps, redness, pain, discoloration, and
itching. With JUVÉDERM VOLUMA® XC, most side
effects were moderate (uncomfortable) and lasted 2 to 4
weeks. For JUVÉDERM VOLBELLA® XC, most side
effects were mild or moderate and lasted 30 days or less.
One of the risks with using these products is unintentional
injection into a blood vessel, and, while rare, the complications
can be serious and may be permanent. These complications, which
have been reported for facial injections, can include vision
abnormalities, blindness, stroke, temporary scabs, or permanent
scarring.
As with all skin injection procedures, there is a risk of
infection.
To report a side effect with JUVÉDERM VOLUMA® XC
or JUVÉDERM VOLBELLA® XC, or for product information,
please call Allergan at 1-800-433-8871. Please also visit
Juvederm.com for more information.
Available by prescription only.
RHOFADE® (oxymetazoline HCl) cream 1%
Important Safety Information
Indication
RHOFADE® (oxymetazoline HCl)
cream 1% is a prescription medicine used on the skin to treat
ongoing facial redness due to rosacea in adults.
Important Safety Information
Before you use RHOFADE® cream, tell
your doctor about all your medical conditions, including if you
have: heart, blood vessel, or blood pressure problems, or
narrow-angle glaucoma (get medical help if these conditions
worsen); problems with blood circulation or have had a stroke;
Sjögren's syndrome; scleroderma; Raynaud's phenomenon;
thromboangiitis obliterans; or irritated skin or open sores on the
face.
Tell your doctor about your medications, as use with
RHOFADE® cream may cause serious side effects.
The most common side effects at the application site include:
skin reactions, worsening of rosacea pimples, itching, redness, and
pain.
You may report side effects to the FDA at 1-800-FDA-1088.
Please see full Product Information for
RHOFADE® cream.
SkinMedica®
The SkinMedica® product described here is intended to meet the
FDA's definition of a cosmetic product, an article applied to the
human body to cleanse, beautify, promote attractiveness, and alter
appearances. This SkinMedica® product is not intended to be a drug
product that diagnoses, treats, cures or prevents any disease or
condition. This product has not been approved by the FDA and the
statements on these pages have not been evaluated by the FDA.
References:
1. Data on File, Allergan; Proforma Sales JUVÉDERM
VOLUMA® XC, 2015.
2. Bernardin A et al. VYCROSS®: An innovative
dermal filler technology. Poster presented at: 1st Annual
Anti-Aging Medicine European Congress (AMEC); October 11-12, 2013; Paris, France.
3. JUVÉDERM VOLBELLA® XC Patient Labeling,
2016.
4. JUVÉDERM VOLUMA® XC Patient Labeling,
2016.
5. RHOFADE® Prescribing Information,
2017.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry with
65+ mid-to-late stage pipeline programs currently in
development.
Allergan's success is powered by our more than 18,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2016 and Allergan's Quarterly Report on Form 10-Q for the
period ended June 30, 2017. Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
© 2017 Allergan. All rights reserved. All trademarks are the
property of their respective owners.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Daphne
Karydas
|
|
(862)
261-8006
|
|
|
|
Media:
|
|
Mark
Marmur
|
|
(862)
261-7558
|
|
|
|
Ember
Garrett
|
|
(714)
246-3525
|
|
|
|
Lisa Kim
|
|
(714)
246-3843
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/allergan-innovation-recognized-with-three-2017-allure-best-of-beauty-breakthrough-awards-300521804.html
SOURCE Allergan plc